Nature Publishing Group, publisher of Nature, and other science journals and reference works NATURE.COM NATURE NEWS NATUREJOBS NATUREEVENTS ABOUT NPG
Help Nature.com site index  
Leukemia
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
July 2001, Volume 15, Number 7, Pages 1133-1136
Table of contents    Previous  Article  Next   [PDF]
Correspondence
Further characterization of complex chromosomal rearrangements in myeloid malignancies: spectral karyotyping adds precision in defining abnormalities associated with poor prognosis
M D Odero1, K M Carlson2, M J Calasanz1 and J D Rowley2

1Department of Genetics, University of Navarra, Pamplona, Spain

2Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA

Correspondence to: M D Odero, Department of Genetics, University of Navarra, C/Irunlarrea s/n, 31008-Pamplona, Spain; Fax: 34-948-425649

TO THE EDITOR

In the last 30 years, information provided by cytogenetic analysis has become indispensable for the clinical management of patients with hematological malignancies. In acute myeloid leukemia (AML), the favorable prognostic subgroup is defined by the presence of leukemic blasts with t(15;17), t(8;21), or inv(16). The unfavorable cases are those with abnormalities involving more than two chromosomes, monosomy 5/5q- or 7/7q-, or rearrangements of the long arm of chromosome 3. The survival rate of this group is less than 20% at 5 years. These patients represent a considerable therapeutic challenge for whom no current treatment approach is satisfactory.1 The patients with a normal karyotype or cytogenetic abnormalities that are not included in these other categories are characterized as having an intermediate risk of relapse.1,2 In myelodysplastic syndromes (MDS), abnormalities of 7q or a complex karyotype are also unfavorable prognostic factors.3 Improvements in treatment of AML, t-AML and MDS have resulted in high complete remission rates even in patients with unfavorable cytogenetics; however, the majority of patients relapse.1,3 Therefore, further genetic studies redefining the patients included in the poor prognostic group are necessary.

In order to characterize the karyotype more precisely, we analyzed 18 samples from patients with myeloid malignancies and a complex karyotype using three different techniques: G-banding, fluorescence in situ hybridization (FISH), and spectral karyotyping (SKY). The SKY probe mixture and hybridization reagents were obtained from Applied Spectral Imaging (Carlsbad, CA, USA). Slides for spectral karyotyping were hybridized as previously described.4 For analysis of cases that had complex markers or non-obvious chromosome rearrangements, FISH experiments were performed using the appropriate painting or centromere-specific probes (Vysis, Downers Grove, IL, USA).

All 18 cases were successfully analyzed using SKY. In the three cases with complete G-band analysis (cases 6, 8, 14), SKY confirmed the G-banding results. In the other 15 cases, the use of SKY substantially improved the precision of karyotype analysis of malignant cells, detecting several unexpected aberrations. The approach of combining three different cytogenetic techniques allowed the identification of hidden translocations and the reconstruction of complex rearrangements. The complete karyotypes after the combined analysis are given in Table 1. Deletions and unbalanced translocations in samples with complex aberrations were particularly prone to misinterpretation based on G-banding alone, especially when chromosomal regions that have a similar G-banding pattern were involved. In 13 cases (1, 2, 4, 5, 7, 9, 11, 12, 13, 15, 16, 17, 18), chromosome material from total or partial monosomies detected by G-banding was found in derivative or marker chromosomes. On the other hand, in seven cases (7, 9, 11, 13, 15, 16, 18) deletions were actually found to be translocations after SKY. This is especially important in cases with aberrations with prognostic significance. Thirteen cases (72%) had monosomy 5 or 7, or abnormalities of 3q, 5q or 7q. SKY confirmed the G-banding results in six of these cases and detected new abnormalities in seven others. Three of our cases were -5 (cases 7, 9 and 13); based on SKY, all three were changed to a deletion 5q, eg loss of chromosome 5, bands 5q31 to 5q33 (case 7); translocation of parts of 5 to a der(7) and a der(13), that resulted in loss of chromosome 5, bands 5q13 to 5q33, in case 9. In case 13, 5q was thought to be on chromosome 18, however, SKY demonstrated that a der(5), chromosome break in 5q13, was joined to 17q. SKY confirmed the del(5q) in four cases (2, 3, 4, 15) and clarified the nature of the 5;17 rearrangement in a fifth case (case 5). In case 11, del(5)(q15q33) was shown to involve a 5;6 translocation with a deletion of part of 5q in this process (Figure 1). In case 16, the add(5)(q13) was really a der(5)t(2;5)(p25;q13). Minus 5 is associated with a dismal prognosis.2 Therefore modifying the analysis could move these patients from an extremely poor prognosis to one that is less poor. Eight patients had -7; SKY confirmed this in six patients and revealed that part of 7 was on a der(6) (case 9) or a der(15) (case 13). The analysis in each of the three cases (7,11,16) with a del(7q) or ring chromosome was modified based on SKY (Table 1).

Other studies using SKY have shown its power in resolving the full spectrum of chromosome abnormalities in tumors, as well as documenting new recurring breakpoints in lymphoproliferative disorders.4,5,6 Two recent papers have focused on the ability of this technique to detect hidden aberrations in myeloproliferative disorders,7,8 but this is the first report focusing on a group of myeloid malignancies with poor outcome. The results of Mohr et al7 and Zhang et al8 showed SKY could identify undetected cytogenetic aberrations in only two of 47 karyotypically normal AML. These results, and the fact this is a laborious and expensive technique, suggest that SKY is not likely to have a clinical impact for the study of normal G-banding cases. Although SKY did not detect any unexpected recurring aberrations in the cases we studied, our work confirms that this technique is a useful tool to resolve uncertainties of the G-banding analysis in cases with complex karyotypes. A recent report has shown yet again the importance of karyotype as a critical independent determinant of outcome in AML, especially in older patients.2 Our study shows SKY could provide further precision to refine the poor prognostic groups in myeloid malignancies. As indicated by others, this technique should be used to complement G-banding analysis.4,5 The conventional karyotype provides an accurate description of the bands involved in the rearrangements and permits an analysis of a larger number of clones. In many rearrangements the breakpoints on the SKY-painted chromosomes were identified by comparing the corresponding DAPI banding and G-banded karyotype of the same tumor (Figure 1).

In conclusion, SKY can be an important tool to characterize aberrations in cases with complex karyotypes. The detection of subtle translocations in chromosomes thought to be deletions using G-banding shows that SKY can provide a focus for further FISH and molecular studies, especially in cases with 3q, 5q and 7q rearrangements. Moreover, SKY and other techniques of molecular cytogenetics, could help to identify specific subtypes of the disease with prognostic significance. Further studies in a larger number of cases are needed to show if any of the translocations found are recurrent, and to supply critical information on the correct implication of monosomy in myeloid malignancies.

Acknowledgements

This work was supported in part by a grant of the Departamento de Salud, Gobierno de Navarra, Spain (MDO), and by the National Cancer Institute (CA42557 and CA84405 to JDR) and the Spastic Paralysis Foundation, Illinois-Eastern Iowa District of Kiwanis International to JDR. We thank M Le Beau, D Roulston and M Isaacson for access to data management and for the patient karyotypic data.

References

1 Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062, MEDLINE

2 Grimwade D, Harrison G, Walker H, Harrison CJ, Wheatley K, Hann I, Rees J, Stevens R, Webb DKH, Gibson BE, Burnett AK, Goldstone AH. On behalf of UK MRC Leukaemia Working Parties. Hierarchical cytogenetic classification is highly predictive of outcome in AML arising at all ages: analysis of 4225 cases entered in the UK MRC leukaemia trials. Blood 2000; 96: 825a,

3 Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann HG, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA, Barnett MJ. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910-1917, MEDLINE

4 Rowley JD, Reshmi S, Carlson K, Roulston D. Spectral karyotype analysis of T-cell acute leukemia. Blood 1999; 93: 2038-2042, MEDLINE

5 Veldman T, Vignon C, Schrock E, Rowley JD, Ried T. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping. Nat Genet 1997; 15: 406-410, MEDLINE

6 Ning Y, Liang JC, Nagarajan L, Schrock E, Ried T. Characterization of 5q deletions by subtelomeric probes and spectral karyotyping. Cancer Genet Cytogenet 1998; 103: 170-172, MEDLINE

7 Mohr B, Bornhauser M, Thiede C, Schakel U, Schaich M, Illmer T, Pascheberg U, Ehninger G. Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2000; 14: 1031-1038, MEDLINE

8 Zhang FF, Murata-Collins JL, Gaytan P, Forman SJ, Kopecky KJ, Willman CL, Appelbaum FR, Slovak ML. Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. Genes Chromosomes Cancer 2000; 28: 318-328, MEDLINE

9 Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD. Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 2001; 31: 134-142, MEDLINE

Figures

Figure 1 SKY analysis of case 11 (clone 4). (a) Spectral metaphase. (b) Classified metaphase. (c) Partial G-band and SKY karyotypes illustrating the power of the combined approach to clarify complex chromosome rearrangements. Normal homologues are included whenever possible to facilitate comparison. See text for detailed karyotype description.

Tables

Table 1 Refinement of chromosome aberrations by G-banding with spectral karyotyping

Received 10 October 2000; accepted 19 March 2001
July 2001, Volume 15, Number 7, Pages 1133-1136
Table of contents    Previous  Article  Next    [PDF]
Privacy Policy © 2001 Nature Publishing Group